ミノキジルのローションが市販されていますが、実は４０％の人しか効きません。全員効果があると思っているかもしれませんが、ミノキシジルを変換するスルフォトランスフェラーゼの活性が低い人は効果が薄いです。
ですので、まずこの酵素が治療受ける人に存在するかを測る必要があります。
それがMinoスカルプチェックです。
毛根に存在する酵素を直接測ることによって測定することができます。日本で唯一測定できるのは東京衛生検査所だけです。
ではどのくらいの人がミノキシジルが効果的なのでしょうか？以下の論文はインドにおける頻度を示しています。これによるとミノキジルは24％から52％の人しか効果がなかったと書いてあります。
インドの人と日本人では遺伝子的に異なるため、東京衛生検査所でも同様の検査を行ったが約４０％の人しかこの酵素が発現されておらず、６０％のひとはミノキシジルが効果的でないことが分かっています。
リ〇ップなどの市販されているミノキシジル外用薬を使う前にするフォトランスフェラーぜ酵素の発現量を検査することは重要です。効果がないのに使うのはお金の無駄遣いになります。
Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men
Monitoring Editor: Alexander Muacevic and John R Adler
Sandeep Sattur,1,2 Abhay Talathi,3 Geetanjali Shetty,4 Shehnaz Arsiwala,5 Rickson Pereira,6,7 and Dhiraj Dhoot8
Author information Article notes Copyright and License information PMC Disclaimer
Abstract
Introduction
Patients with androgenetic alopecia (AGA), who use alcohol-based topical minoxidil solutions, frequently experience localized irritation, dryness, and scalp redness. In this study, we compared the safety and effectiveness of topical 5% cetosomal minoxidil solution to those of topical 5% alcohol-based minoxidil solution in Indian men with AGA.
Methods
In this randomized, open-label study, male patients with AGA were randomized 1:1 to receive either solutions twice daily for 16 weeks. Efficacy endpoints included changes in basic and specific (BASP) grading, improvement in the trichoscopy score, and global photography at week 16 from baseline, whereas safety was evaluated by adverse events reported by patients and hair-related quality of life (QoL) using the Hairdex-29 questionnaire.
Results
Of the 80 patients, only 40 completed the study and were considered for complete analysis. Twelve out of 23 patients (52%) in the cetosomal minoxidil group and four out of 17 patients (24%) in the alcohol-based minoxidil group showed a positive increase in hair growth according to the trichoscopy score (p=0.1). According to the BASP grading system, nine patients (39%) and five patients (29%) in the cetosomal and alcohol-based minoxidil groups, respectively, showed improvement (p=0.73). Similarly, 19 (83%) and 10 (59%) patients in the cetosomal and alcohol-based minoxidil groups, respectively, reported positive hair growth on the global photography assessment (p=0.15). All the patients tolerated the treatment well, with no discontinuation in either group. There were four adverse events in the cetosomal minoxidil group, reported by two (9%) patients, whereas in the alcohol-based minoxidil group, 10 adverse events were reported by seven (41%) patients (p=0.02). In addition, the mean Hairdex-29 score of 40.26±4.71 at baseline improved to 32.32±3.35 in the cetosomal group, whereas it improved to 34.64±3.41 from 39.64±4.98 in the other group (p=0.03).
Conclusions
The 5% cetosomal minoxidil group showed improved safety but similar efficacy when administered twice daily. Therefore, cetosomal minoxidil may be a better option for treating AGA in males who are sensitive or nontolerant to alcoholic formulations.
Keywords: india, hairdex-29, safety, efficacy, conventional minoxidil, cetosomal minoxidil, androgenetic alopecia
